Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8718 |
High Similarity |
NPD7075 |
Discontinued |
0.8609 |
High Similarity |
NPD2533 |
Approved |
0.8609 |
High Similarity |
NPD2532 |
Approved |
0.8609 |
High Similarity |
NPD2534 |
Approved |
0.8581 |
High Similarity |
NPD6801 |
Discontinued |
0.8571 |
High Similarity |
NPD4380 |
Phase 2 |
0.8526 |
High Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8523 |
High Similarity |
NPD2800 |
Approved |
0.8487 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8408 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8366 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.8365 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.8301 |
Intermediate Similarity |
NPD6799 |
Approved |
0.828 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.8278 |
Intermediate Similarity |
NPD1243 |
Approved |
0.8258 |
Intermediate Similarity |
NPD920 |
Approved |
0.8243 |
Intermediate Similarity |
NPD6651 |
Approved |
0.8242 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.8239 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.8239 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.8228 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8212 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8182 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.8176 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.8146 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8146 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8129 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.8117 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.8101 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.8095 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.8092 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8079 |
Intermediate Similarity |
NPD2796 |
Approved |
0.8075 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8075 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8063 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8054 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.8054 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.8025 |
Intermediate Similarity |
NPD5403 |
Approved |
0.8013 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7975 |
Intermediate Similarity |
NPD919 |
Approved |
0.7952 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7952 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7952 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7952 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7949 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7939 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7939 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7927 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7917 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7914 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7904 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7901 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7898 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7879 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.787 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.787 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7867 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7853 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7848 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7836 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7831 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7824 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7806 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7763 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7756 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7756 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7756 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7733 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7733 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7727 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7719 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7706 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7662 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.763 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7616 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7616 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7602 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.756 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7548 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7532 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7515 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7514 |
Intermediate Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.7485 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7483 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7483 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7468 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7458 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7452 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7452 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7452 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7452 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7452 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.744 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7436 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7432 |
Intermediate Similarity |
NPD9717 |
Approved |
0.74 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7389 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7386 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7362 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7358 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7355 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7355 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7353 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7349 |
Intermediate Similarity |
NPD37 |
Approved |
0.7342 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7342 |
Intermediate Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.7326 |
Intermediate Similarity |
NPD2403 |
Approved |
0.7321 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7321 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7321 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7296 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7289 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7288 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7288 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7285 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7278 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7278 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7267 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7267 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.725 |
Intermediate Similarity |
NPD2654 |
Approved |
0.7249 |
Intermediate Similarity |
NPD7584 |
Approved |
0.7235 |
Intermediate Similarity |
NPD5537 |
Clinical (unspecified phase) |
0.7233 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7215 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.7213 |
Intermediate Similarity |
NPD4360 |
Phase 2 |
0.7213 |
Intermediate Similarity |
NPD4363 |
Phase 3 |
0.7212 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7209 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7207 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7182 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7174 |
Intermediate Similarity |
NPD4361 |
Phase 2 |
0.7174 |
Intermediate Similarity |
NPD4362 |
Clinical (unspecified phase) |
0.7169 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7161 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7161 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.716 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7134 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD1019 |
Discontinued |
0.712 |
Intermediate Similarity |
NPD7585 |
Approved |
0.7101 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7095 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7091 |
Intermediate Similarity |
NPD5049 |
Phase 3 |
0.7088 |
Intermediate Similarity |
NPD4287 |
Approved |
0.7073 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7073 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7072 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.707 |
Intermediate Similarity |
NPD943 |
Approved |
0.707 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7068 |
Intermediate Similarity |
NPD7583 |
Approved |
0.7062 |
Intermediate Similarity |
NPD1729 |
Discontinued |
0.7059 |
Intermediate Similarity |
NPD3267 |
Approved |
0.7059 |
Intermediate Similarity |
NPD3266 |
Approved |
0.7051 |
Intermediate Similarity |
NPD411 |
Approved |
0.7045 |
Intermediate Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.7032 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7029 |
Intermediate Similarity |
NPD7784 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7013 |
Intermediate Similarity |
NPD5647 |
Approved |
0.701 |
Intermediate Similarity |
NPD7783 |
Phase 2 |
0.701 |
Intermediate Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.6995 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6993 |
Remote Similarity |
NPD3225 |
Approved |
0.6983 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6974 |
Remote Similarity |
NPD1608 |
Approved |
0.6964 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6962 |
Remote Similarity |
NPD1613 |
Approved |
0.6962 |
Remote Similarity |
NPD4307 |
Phase 2 |
0.6962 |
Remote Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD9493 |
Approved |
0.6959 |
Remote Similarity |
NPD5353 |
Approved |
0.6951 |
Remote Similarity |
NPD3887 |
Approved |
0.6951 |
Remote Similarity |
NPD2354 |
Approved |
0.6951 |
Remote Similarity |
NPD6190 |
Approved |
0.6949 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6943 |
Remote Similarity |
NPD3764 |
Approved |
0.6937 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6931 |
Remote Similarity |
NPD6777 |
Approved |
0.6931 |
Remote Similarity |
NPD6776 |
Approved |
0.6931 |
Remote Similarity |
NPD6782 |
Approved |
0.6931 |
Remote Similarity |
NPD6780 |
Approved |
0.6931 |
Remote Similarity |
NPD6781 |
Approved |
0.6931 |
Remote Similarity |
NPD6779 |
Approved |
0.6931 |
Remote Similarity |
NPD6778 |
Approved |
0.6918 |
Remote Similarity |
NPD1933 |
Approved |
0.6914 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6908 |
Remote Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6908 |
Remote Similarity |
NPD1610 |
Phase 2 |
0.6901 |
Remote Similarity |
NPD5761 |
Phase 2 |
0.6901 |
Remote Similarity |
NPD5760 |
Phase 2 |
0.6886 |
Remote Similarity |
NPD6273 |
Approved |
0.6882
|
Remote Similarity |
NPD5889 |
Approved |